Is Buying Stock Like BeiGene, Ltd. (BGNE) After Such Increase Winning Strategy?

February 15, 2018 - By Darrin Black

The stock of BeiGene, Ltd. (NASDAQ:BGNE) is a huge mover today! The stock increased 5.72% or $7.39 during the last trading session, reaching $136.63. About 150,069 shares traded. BeiGene, Ltd. (NASDAQ:BGNE) has risen 36.36% since February 15, 2017 and is uptrending. It has outperformed by 19.66% the S&P500.
The move comes after 6 months positive chart setup for the $7.27 billion company. It was reported on Feb, 15 by Barchart.com. We have $147.56 PT which if reached, will make NASDAQ:BGNE worth $581.52 million more.

Analysts await BeiGene, Ltd. (NASDAQ:BGNE) to report earnings on March, 28. They expect $-1.74 EPS, down 65.71 % or $0.69 from last year’s $-1.05 per share. After $2.54 actual EPS reported by BeiGene, Ltd. for the previous quarter, Wall Street now forecasts -168.50 % negative EPS growth.

More notable recent BeiGene, Ltd. (NASDAQ:BGNE) news were published by: Marketwatch.com which released: “BeiGene stock surges 12% on Celgene cancer collaboration” on July 06, 2017, also Marketwatch.com with their article: “BeiGene, first IPO of 2016, begins trading above issue price” published on February 03, 2016, Schaeffersresearch.com published: “Biotech Stocks ImmunoGen, BeiGene Surge to New Highs” on July 06, 2017. More interesting news about BeiGene, Ltd. (NASDAQ:BGNE) were released by: Quotes.Wsj.com and their article: “News BeiGene Ltd. ADRBGNE” published on January 31, 2016 as well as Marketwatch.com‘s news article titled: “BeiGene Ltd. ADR” with publication date: February 03, 2016.

BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops molecularly-targeted and immuno-oncology drugs for the treatment of cancer. The company has market cap of $7.27 billion. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations. It currently has negative earnings. The Company’s preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: